Show simple item record

dc.contributor.authorWithers, Nicholas J.
dc.date.accessioned2021-03-22T12:46:40Z
dc.date.available2021-03-22T12:46:40Z
dc.date.issued2021-02-01
dc.identifier.citationGriese M et al. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 Feb 1;203(3):381-385.en_US
dc.identifier.pmid32969708
dc.identifier.doi10.1164/rccm.202008-3176LE
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/621675
dc.language.isoenen_US
dc.publisherAtyponen_US
dc.relation.urlhttps://www.atsjournals.org/doi/10.1164/rccm.202008-3176LE?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmeden_US
dc.rightsCopyright © 1987-2020 American Thoracic Society, All Rights Reserved.en_US
dc.subjectAllelesen_US
dc.subjectAminophenolsen_US
dc.subjectBenzodioxolesen_US
dc.subjectCystic Fibrosisen_US
dc.subjectCystic Fibrosis Transmembrane Conductance Regulatoren_US
dc.subjectDrug Combinationsen_US
dc.subjectIndolesen_US
dc.subjectPyrazolesen_US
dc.subjectPyridinesen_US
dc.subjectQuinolinesen_US
dc.subjectTreatment Outcomeen_US
dc.subjectWessex Classification Subject Headings::Respiratory medicineen_US
dc.titleSafety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trialen_US
dc.typeClinical Trial, Phase IIIen_US
dc.identifier.journalAmerican Journal of Respiratory and Critical Care Medicineen_US
dc.type.versionPublisheden_US
dc.description.admin-noteaccepted version (12 month embargo)en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record